Mechanism and Effect of Beta-Blockers on Pancreatic Adenocarcinoma: A Literature Review.
Beta-adrenergic pathway
Beta-blockers
Cancer
Pancreatic adenocarcinoma
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
29
10
2020
accepted:
24
11
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
ppublish
Résumé
Pancreatic adenocarcinoma has a poor 5-year survival rate despite many advancements in pharmacotherapies. Studies have suggested the involvement of β-adrenergic pathway in the progression of pancreatic adenocarcinoma. Animal experiments and retrospective trials have reported the use of beta-blockers as potential chemo-preventative agents. This review aims to discuss β-adrenergic physiology as it relates to the progression of pancreatic adenocarcinoma and review outcomes on the use of beta-blockers for its treatment.
Identifiants
pubmed: 33447308
doi: 10.14740/jocmr4387
pmc: PMC7781287
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
753-757Informations de copyright
Copyright 2020, Upadhyaya et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Toxicol Appl Pharmacol. 2007 Jun 15;221(3):261-7
pubmed: 17498763
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Carcinogenesis. 2000 Feb;21(2):139-46
pubmed: 10657949
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Allergy Clin Immunol. 2006 Jan;117(1):18-24; quiz 25
pubmed: 16387578
Anticancer Drugs. 2009 Jul;20(6):477-82
pubmed: 19387337
Carcinogenesis. 2001 Mar;22(3):473-9
pubmed: 11238189
Oncotarget. 2010 Nov;1(7):628-38
pubmed: 21317458
BMC Cancer. 2016 Mar 12;16:212
pubmed: 26968702
Onco Targets Ther. 2018 Aug 20;11:4913-4944
pubmed: 30174436
Pancreatology. 2016 May-Jun;16(3):423-33
pubmed: 27083074
Nature. 2009 May 21;459(7245):356-63
pubmed: 19458711
Oncol Rep. 2009 Oct;22(4):825-30
pubmed: 19724861
Cancers (Basel). 2015 Jul 17;7(3):1292-312
pubmed: 26193320
Oncol Rep. 2016 Jun;35(6):3135-42
pubmed: 27035124
Mol Pharmacol. 2006 Feb;69(2):618-28
pubmed: 16269536
J Pathol. 2009 Aug;218(4):437-45
pubmed: 19274673
J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S313-7
pubmed: 12464941
Int J Epidemiol. 2015 Feb;44(1):186-98
pubmed: 25502106
Cancer Res. 1999 May 1;59(9):2223-8
pubmed: 10232612
Mol Cancer. 2011 Nov 26;10:146
pubmed: 22118662
Oncotarget. 2016 Jun 21;7(25):38539-38550
pubmed: 27413117
Pharmaceuticals (Basel). 2020 May 26;13(6):
pubmed: 32466499
J Natl Cancer Inst. 2013 Nov 20;105(22):1694-700
pubmed: 24203988
Crit Rev Oncol Hematol. 2019 Jun;138:173-177
pubmed: 31092374
Drugs. 1984;28 Suppl 2:1-15
pubmed: 6098436
Cancer Immunol Immunother. 2014 Nov;63(11):1115-28
pubmed: 25307152
Biomed J. 2019 Jun;42(3):155-165
pubmed: 31466709
Cancer Res. 2017 Jul 1;77(13):3700-3707
pubmed: 28473530
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Crit Rev Oncol Hematol. 2004 Mar;49(3):179-86
pubmed: 15036258
Pancreas. 2009 Jan;38(1):94-100
pubmed: 19106745
Hepatogastroenterology. 2012 May;59(115):889-93
pubmed: 22020907
Cancer Res. 2006 Nov 1;66(21):10357-64
pubmed: 17079456
Cancer Cell. 2018 Jan 8;33(1):75-90.e7
pubmed: 29249692